Mechanism of QHF-cisplatin against hepatocellular carcinoma in a mouse model

被引:6
作者
Chen, Tao [1 ]
Yuan, Shen-Jun [2 ]
Wang, Jing [3 ]
Hu, Wei [1 ,2 ]
机构
[1] China Three Gorges Univ, Level TCM Pharmacol Res Lab 3, China TCM Adm, Med Sci Coll, Yichang 443002, Hubei Province, Peoples R China
[2] China Three Gorges Univ, Med Sci Coll, Yichang 443002, Hubei Province, Peoples R China
[3] Xinyi Peoples Hosp, Dept Med, Xinyi 221400, Jiangsu, Peoples R China
关键词
QHF formula; Cisplatin; Hepatocellular carcinoma; H-22; cells; Hepatocyte growth factor; c-Met; TRADITIONAL CHINESE MEDICINE; CANCER-THERAPY; HEPATITIS-B; ACTIVATION; PATHWAYS; KINASES;
D O I
10.3748/wjg.v21.i35.10126
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To study the effects of QHF-cisplatin on H-22 hepatocellular carcinoma (HCC) and their mechanisms of action. METHODS: Sixty BALB/c mice were randomly divided into a model group (n = 48) and a normal control group (n = 12). An HCC xenograft tumor was created by injecting H-22 cells directly into the liver parenchyma of the mice. The 48 BALB/c mice in the model group were randomly divided into four groups: QHF, DDP (cisplatin), QHF plus DDP, and model control. The inhibitory effects of these drugs on tumor growth were evaluated by calculating the rate of tumor growth inhibition. The mice were examined by observing their general condition, body weight and survival time. Changes in tumor tissue were observed under an optical microscope. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and a-fetoprotein (AFP) levels in serum were measured. Hepatocyte growth factor (HGF), c-mesenchymal-epithelial transition (c-Met) factor, phosphorylated (p)-c-Met, p38, p-p38, extracellular signal-regulated kinase (ERK), p-ERK and vascular endothelial growth factor (VEGF) levels were evaluated in tumor and liver tissues using western blotting. RESULTS: Compared with the DDP group, a lower incidence of toxic reactions and a higher survival time were observed in the QHF plus DDP group. Tumor weight was significantly lower in the QHF, DDP and QHF plus DDP groups than in the model control group (0.24 +/- 0.07, 0.18 +/- 0.03 and 0.14 +/- 0.01 g vs 0.38 +/- 0.05 g, respectively), and the differences were statistically significant (P < 0.01). The rate of tumor growth inhibition in the QHF, DDP and QHF plus DDP groups was 38.7%, 52.6% and 63.5%, respectively. AST, ALT and AFP levels in serum were significantly lower in the QHF, DDP and QHF plus DDP groups compared to the model control group (P < 0.05). Similarly, HGF, p-c-Met, p-p38, p-ERK and VEGF levels in tumor tissue were significantly lower in the QHF, DDP and QHF plus DDP groups (P < 0.05). CONCLUSION: QHF and DDP have an antiangiogenic effect on H22 HCC in mice. QHF inhibits tumor growth via blocking the HGF/c-Met signaling pathway, inhibiting p38, ERK and VEGF signaling.
引用
收藏
页码:10126 / 10136
页数:11
相关论文
共 31 条
[1]   MET Signaling Pathway: A Rational Target for Cancer Therapy [J].
Appleman, Leonard J. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (36) :4837-4838
[2]   Targeting the Hepatocyte Growth Factor-cMET Axis in Cancer Therapy [J].
Blumenschein, George R., Jr. ;
Mills, Gordon B. ;
Gonzalez-Angulo, Ana M. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (26) :3287-3296
[3]   Persistent ERK/MAPK Activation Promotes Lactotrope Differentiation and Diminishes Tumorigenic Phenotype [J].
Booth, Allyson ;
Trudeau, Tammy ;
Gomez, Crystal ;
Lucia, M. Scott ;
Gutierrez-Hartmann, Arthur .
MOLECULAR ENDOCRINOLOGY, 2014, 28 (12) :1999-2011
[4]   Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion [J].
Bourboulia, Dimitra ;
Stetler-Stevenson, William G. .
SEMINARS IN CANCER BIOLOGY, 2010, 20 (03) :161-168
[5]   The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide [J].
Brantley-Finley, C ;
Lyle, CS ;
Du, LH ;
Goodwin, ME ;
Hall, T ;
Szwedo, D ;
Kaushal, GP ;
Chambers, TC .
BIOCHEMICAL PHARMACOLOGY, 2003, 66 (03) :459-469
[6]  
Chen T, 2010, ZHONGGUO SHIYAN FANG, V16, P137
[7]  
Chen T, 2006, CHINESE MED EFFECTIV, Patent No. ZL 2006 1 0135871.X
[8]  
Chen T, 2010, SHIJIE HUAREN XIAOHU, V18, P137
[9]   Hepatic Stellate Cell Coculture Enables Sorafenib Resistance in Huh7 Cells through HGF/c-Met/Akt and Jak2/Stat3 Pathways [J].
Chen, Weibo ;
Wu, Junhua ;
Shi, Hua ;
Wang, Zhongxia ;
Zhang, Guang ;
Cao, Yin ;
Jiang, Chunping ;
Ding, Yitao .
BIOMED RESEARCH INTERNATIONAL, 2014, 2014
[10]   A Chinese herbal formula, Yi-Qi-Fu-Sheng, inhibits migration/invasion of colorectal cancer by down-regulating MMP-2/9 via inhibiting the activation of ERK/MAPK signaling pathways [J].
Deng, Wanli ;
Sui, Hua ;
Wang, Qiaolin ;
He, Nana ;
Duan, Chunyan ;
Han, Liang ;
Li, Qi ;
Lu, Ming ;
Lv, Shuqin .
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2013, 13